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Abstract 
 
Background. Adherence to validated guidelines is crucial to guide management of patients 
hospitalized with community-acquired pneumonia (CAP). Data describing real-life 
management and treatment of CAP are limited.  
Objective. We aimed to evaluate the adherence to guidelines over time, and to assess its 
impact on all-cause mortality and clinical outcomes. 
Methods. We retrospectively compared two cohorts of patients admitted to hospital, 
throughout 2005, just after implementation of a local clinical pathway based on CAP 
international guidelines, and 7 years later over 2012. We included all patients with a 
diagnosis of pneumonia and/or related complications. 
Results. 564 patients were included. Pneumonia Severity Index calculation was better 
documented in 2012 (25.23%) compared to 2005 (17.70%; p=0.032), but adherence to 
guideline empirical antibiotic therapy was lower in 2012 (56.70%) than in 2005 (68.75%; 
p=0.004). Performance of guideline recommended urinary antigen tests was higher in 2012 
and associated with 57.3% lower odds of in-hospital mortality (95%CI 15.0% to 78.5%) and 
with 65.9% lower odds of 30-day mortality (95%CI 31.5% to 83.0%). Adherence to 
empirical antibiotic therapy was associated with 2.9 days lower mean length of hospital stay 
(95%CI -4.2 to -1.6 days) and with 2.0 days lower mean duration of antibiotic therapy 
(95%CI -3.3 to -0.7 days). 
Conclusions. Adherence to guidelines changed over time, with some effects on mortality and 
with an apparent reduction in length of hospital stay and duration of antibiotic therapy.  
Specific clinical training and hospital control policies could achieve greater adherence to 
guidelines and thus reduce burden on hospital services. 
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INTRODUCTION 
 
Community-acquired pneumonia (CAP) is the leading cause of death for infectious disease 
worldwide, representing a considerable cause of morbidity and mortality, especially among 
hospitalized patients. [1, 2] Both prevalence and hospitalization rates are particularly high in 
elderly and comorbid patients;[3, 4] for people over 65 years early readmission to hospital 
has also been increasing. [5] Today, if recurrences are excluded, the mean European length of 
hospital stay is 9.0 days and in-hospital mortality rates vary from 0% to 17.5% across 
countries. [6] 
Given the high burden of disease and the wide spectrum of clinical severity, use of validated 
guidelines is crucial in guiding diagnostic and therapeutic approaches. Adherence to 
guidelines has been found to improve clinical outcomes, independently on contextual and 
patient-specific variables (such as the decision to hospitalize and the rapidity of 
administration of the first antibiotic dose), [6] and to reduce unnecessary hospitalizations and 
readmissions, length of hospital stay, costs, and mortality. [7-19] 
Although adherence to guidelines varies among clinicians and is conditioned by various 
factors, [20] site of care, i.e. management outside or inside hospital, and correct timing of 
antibiotic therapy are vital factors in reducing risk of complications and mortality from CAP. 
[21] These aspects, as well as choice of empirical antibiotic therapy, are most critical when 
applying guideline indications. [6] 
 
To comply with international guidelines, in 2005 we implemented a CAP clinical pathway 
(CP) based on American Thoracic Society and British Thoracic Society guidelines, and 
which is still largely compatible with the most updated guidelines available in 2015. [22, 23] 
 
Objectives 
 
We aimed to evaluate to what extent adherence to the local CAP CP in our hospital changed 
over time from 2005 to 2012. We also aimed to evaluate the impact of hospital-wide 
adherence to the local CAP CP over time on (i) in-hospital all-cause mortality, (ii) 30-day all-
cause mortality, (iii) length of hospital stay, and (iv) length of antibiotic therapy. 
 
MATERIAL AND METHODS 
 
This report was written in compliance with the STROBE Statement for observational studies. 
[24] 
Clinical pathway elaboration 
In 2004 we outlined, and in 2005 implemented, a CAP CP based on then current American 
Thoracic Society and British Thoracic Society guidelines. [22, 23] Our intent was to provide 
hospital clinicians with a concise and useful tool to manage patients with CAP. Our CAP CP 
comprises tools (i) to stratify patient risk and select the most appropriate setting of care, (ii) 
to indicate the fundamental diagnostic procedures, (iii) to select the best timing and choice of 
empirical antibiotic therapy (see Figure 1). 
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Study design 
We conducted an observational retrospective study comparing two cohorts of patients 
admitted throughout 2005, the year the local CAP CP was implemented, and again in 2012, 
seven years after its original implementation. All patients in each cohort were followed up for 
30 days from admission. The study was approved by the institutional ethics committee (study 
number: CE 157/14). 
Setting 
The study was conducted in a medium size teaching hospital in North-Western Italy. The 
hospital has 635 beds [25] and a catchment area of approximately half a million people [26]. 
Participants  
We included all patients ≥18 years with a principal or secondary diagnosis of pneumonia 
and/or related complications (pleural effusion, empyema), i.e. ICD-9-CM codes 480-486, 
510, 511, 518, consecutively admitted to our hospital from January 1st to December 31st in 
two separate years of 2005 and 2012. We also manually inspected medical records of patients 
with discharge diagnosis of other pulmonary diseases, in order to capture patients with 
respiratory failure that could represent CAP unreported in the Hospital Discharge Records 
(HDR), and included them in the study whenever appropriate. 
Patients admitted from the community including nursing homes were included in the study in 
accordance with accepted definitions of CAP in the context of the pneumonia triad. [27] 
Patients diagnosed with nosocomial pneumonia, including patients hospitalized for ≥ 2 days 
during the prior 90 days, and immunocompromised patients were excluded. Patients with 
malignancies in active tratment were excluded (we included paitents with malicnancies in 
remission for at least 5 years). Patients whose medical records were not available were 
excluded too. 
Variables 
Variables are detailed in Figure 2. 
We investigated performance indicators suggested by Infectious Diseases Society of 
America/American Thoracic Society (IDSA/ATS) consensus guidelines. [28] 
Data sources and measurements 
Information about patients was gathered through the analysis of medical records, including 
attached documentation and hospital discharge data, by filling out an ad-hoc dataset. The lead 
author and last author manually inspected each record and assessed whether or not the 
clinical practices were in line with those recommended by the local CAP CP. Any 
disagreement was resolved by consensus. 
Data about 30-day mortality from admission were collected through telephone interview. 
Statistical methods 
We carried out descriptive analyses by testing the difference in proportions of binary 
mortality outcomes using χ2 tests and the difference in means of continuous outcomes (length 
of hospital stay, duration of antibiotic therapy) using Student’s t tests.  
To estimate the independent effects of demographic and clinical characteristics on the 
outcomes of interests we utilized four multivariable generalized linear models assuming a 
Binomial distribution of mortality outcomes and a Normal distribution of continuous 
outcomes (length of hospital stay and duration of antibiotic therapy), including appropriate 
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link functions. Regression models included four binary parameters indicating the adherence 
to diagnostic procedures such as execution of blood culture and urinary antigen tests, and the 
adherence to therapeutic interventions such as antibiotic therapy and treatment in intensive 
care unit (ICU). The models also included eight potential confounders of continuous age, sex, 
admission from nursing home or own home, presence of comorbidities, presence of criteria 
for severe CAP as identified by ATS, [28] year of admission to the hospital, stay in a 
respiratory or non-respiratory ward, performance of mechanical ventilation (MV). For the 
mortality binary outcomes, all predictor effects were exponentiated to allow interpretation as 
odds ratio.  
 
RESULTS 
Participants 
564 patients were eligible for inclusion, 243 in 2005 and 321 in 2012 (Figure 3). 
Patients were admitted to 11 hospital departments: A&E, cardiology, infectious diseases, 
ICU, 3 internal medicine divisions, nephrology and dialysis, geriatrics, respiratory, and 
thoracic surgery. 
Information about patients and disease characteristics is illustrated in Tables 1 and 2. 
Mean age and proportion of patients with 5 or more comorbidities were both greater in 2012 
than 2005 (respectively 75.4 vs. 69.0 years; p<0.001; and 19.3% vs. 9.1% of patients; 
p=0.001), despite a significant reduction, in 2012, of proportion of severe CAP as defined by 
ATS criteria [28] (5.6% of patients in 2012 vs. 10.7% in 2005; p=0.026). 
Adherence to diagnostic procedures 
PSI was reported in 25.2% of patients in 2012 vs. 17.7% in 2005 (p=0.032) (Table 3). 
Influenza and pneumococcal vaccination was only recorded for 1 patient. 
Urinary antigen tests for S. pneumoniae and L. pneumophila were performed in a greater 
percentage of patients in 2012 compared to 2005 (56.4% and 57.6% respectively in 2012 vs. 
22.6% and 48.6% in 2005), although there was a significant reduction of other diagnostic 
tests such as blood culture, sputum Gram stain and culture, brushings and bronchial lavage in 
the later year. 
Adherence to therapeutic interventions 
Adherence to clinical pathway in choice of initial empiric antibiotic therapy was 56.7% in 
2012 vs. 68.8% in 2005 (p=0.004) (Table 4). The most common antibiotic treatment schemes 
in both years were levofloxacin (16.5% in 2012 vs. 11.5% in 2005), co-amoxiclav plus 
macrolide (14.9% vs. 11.5%) and levofloxacin plus ceftriaxone (10.0% vs. 12.8%) (data not 
shown in tables). 
There was no evidence of a difference (p=0.183) in the overall duration of antibiotic therapy 
between the two years. 
75.7% of patients admitted in 2012 and 58.9% of those admitted in 2005 appropriately 
received oxygen therapy (p<0.001). 9.35% of patients in 2012 vs. 2.06% in 2005 (p<0.001) 
were treated with Mechanical Ventilation (MV): in detail, 9.0% of patients in 2012 vs. 1.2% 
in 2005 (p<0.001) were treated with non-invasive ventilation (NIV), while 1.3% of patients 
in 2012 vs. 1.7% in 2005 (p=0.691) were treated with invasive ventilation. 
2.2% of patients in 2012 vs. 1.7% in 2005 were treated in ICU (p=0.649). 
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In-hospital and 30-day mortality 
Mortality rates did not change significantly over time. In-hospital mortality was 13.1% in 
2012 and 15.2% in 2005 (p=0.468). Thirty-day mortality was 15.9% in 2012 and 19.6% in 
2005 (p=0.283). 
Adjusted regression analyses (Table 5) showed that mortality was positively associated with 
age and severity of pneumonia and negatively associated with performance of urinary antigen 
tests for S. pneumoniae and L. pneumophila. Mortality was not associated with adherence to 
empirical antibiotic treatment in the CAP clinical pathway. 
With each one year increase in age there was an 8.1% increase in odds of in-hospital 
mortality (95%CI 4.9% to 11.4%) and a 10.5% increase in odds of 30-days mortality (95%CI 
6.8% to 14.3%), while keeping all other predictors constant. Subjects meeting the criteria for 
severe CAP had 74.3% greater odds of in-hospital mortality (95%CI 38.3% to 119.6%) and 
86.8% greater odds of 30-day mortality (95%CI 46.2% to 138.5%) compared to subjects not 
meeting such criteria, while holding all other predictors constant. Performance of urinary 
antigen test was associated with 42.7% lower odds of in-hospital mortality (95%CI 21.5% to 
85.0%) and 34.1% lower odds of 30-day mortality (95%CI 17.0% to 68.5%) compared to 
subjects who were not tested for urinary antigens, while holding all other predictors constant. 
Association between treatment in the ICU and mortality did not reach statistical significance 
at the 5% level. However, treatment in the ICU appears to result in lower odds of both in-
hospital mortality (OR 0.5; 95%CI 0.1 to 2.8) and 30-day mortality (OR 0.3; 95%CI 0.1 to 
2.0). 
Length of hospital stay and duration of antibiotic therapy 
Mean length of hospital stay was 11.5 days in 2012 and 11.7 days in 2005 (p=0.831). Mean 
duration of antibiotic therapy was 12.8 days in 2012 and 13.7 days in 2015 (p=0.183). 
Regression analyses (Table 5) showed adherence to CP antibiotic treatment was associated 
with shorter mean length of hospital stay (-2.9 days; 95%CI -4.2 to -1.6 days) and with 
shorter mean duration of antibiotic therapy (-2.0 days; 95%CI -3.3 to -0.7 days). Admission 
from nursing home was associated with 3.2 days shorter mean length of hospital stay (95%CI 
-5.2 to -1.2 days) compared with admission from home. Mean duration of antibiotic therapy 
was 1.1 days shorter for subjects meeting the criteria for severe CAP (95%CI -1.7 to -0.5 
days). With each one year increase in age there was a 0.1 days increase in mean duration of 
hospital stay (95%CI 0.02 to 0.1 days). Factors associated with increased length of hospital 
stay and duration of antibiotic therapy were: performance of MV (4.6 days; 95%CI 1.7 to 7.6 
days; and 5.0 days; 95%CI 2.1 to 7.9 days respectively), admission to ICU (8.4 days; 95%CI 
3.6 to 13.3 days; and 6.2 days; 95%CI 1.2 to 11.3 days respectively), admission to respiratory 
ward (4.2 days; 95%CI 2.2 to 6.3 days; and 4.4 days; 95%CI 2.4 to 6.4 days respectively) and 
performance of blood cultures (2.6 days; 95%CI 1.3 to 4.0 days; and 2.7 days; 95%CI 1.4 to 
4.0 days respectively). 
DISCUSSION 
 
Our study aimed to provide an analysis of the clinical experience of a medium sized Italian 
teaching hospital, which is likely to be similar in other Western-European settings. 
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Summary of findings 
Adherence to clinical pathway. In our hospital, adherence changed over time. PSI calculation 
was better documented in 2012 compared to 2005, although the proportion of patients that 
received antibiotic therapy adherent to clinical pathway (CP) was lower in 2012. 
Concerning the performance of procedures aimed at obtaining an aetiological diagnosis, 
urinary antigen tests for S. pneumoniae and L. pneumophila were significantly increased in 
2012 compared to 2005, despite a significant reduction in most other diagnostic tests, and 
performed in a significantly greater proportion of patients in the respiratory ward than in 
other wards. 
Mortality. In-hospital and 30-day mortality did not significantly change over time after 
adjustment for adherence to CP, although their point estimates were lower in 2012 compared 
to 2005. In the adjusted regression analyses, age and severity of pneumonia emerged as the 
only predictors associated with an increased risk of in-hospital and 30-day mortality. Patients 
who were tested for urinary antigens had lower odds of in-hospital and 30-day mortality. 
Administration of empirical antibiotic therapy adherent to CP did not have a significant 
impact on mortality from CAP. 
Clinical outcomes. Mean length of hospital stay and mean length of antibiotic therapy 
remained almost unchanged in 2012 and 2005, although they were significantly higher 
among patients hospitalized in the respiratory ward compared to those treated in other 
departments. The administration of an empirical antibiotic therapy adherent to CP was 
associated with a reduction in length of stay and duration of antibiotic therapy. Regression 
analysis confirmed these observations and also provided some evidence of an increased mean 
length of hospital stay and duration of antibiotic therapy associated with execution of blood 
culture, mechanical ventilation (MV) and treatment in ICU. 
Comparison with the literature 
Adherence to clinical pathway. The few studies carried out so far suggest that severity scores 
for pneumonia are rarely used in clinical practice. [21, 29, 30] The results of our study are in 
accord with those reported in the study by Blasi et al., [6] which shows that in Europe the 
application of PSI and CURB-65 appears well below the threshold recommended by the 
guidelines. The most encouraging results emerged from university hospitals, where PSI 
calculation was done in approximately 30% of cases, compared with 6% of cases in non-
university hospitals, and CURB-65 calculations in around 40% vs. 14%. 
In line with Dambrava et al. [31] we demonstrated an association between adherence to CP in 
choice of initial antibiotic therapy and reduced length of hospital stay and duration of 
antibiotic therapy. 
The use of NIV in patients with CAP, both in the literature and in our study, remains 
controversial. [32, 33] 
Mortality. In-hospital mortality in our sample was in line with European hospital mortality 
rates (0% to 17.5%). [6] 
In our study, performance of urinary antigen tests was associated with lower mortality, 
although performance of blood cultures did not yield similar results. This is difficult to 
compare with existing literature, as such variables are often estimated in combination. For 
example, Uematsu et al. [11] in 2014 showed that combined performance of blood culture, 
sputum investigations and urinary antigen tests was associated with a 36% reduction of 30-
day mortality (p <0.001). 
Some studies have found lower mortality when antibiotic treatment is adherent to guidelines. 
[15, 17-19] Menéndez et al. demonstrated that non-adherence was an independent risk factor 
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for treatment failure and mortality. [18] Nevertheless, Dambrava et al. [31] found adherence 
not to be associated with mortality, also consistent with our findings. 
Clinical outcomes. In our study, the average length of hospital stay was in line with the 
European mean duration documented by Blasi et al. (9.0 days). [6] 
Data interpretation 
Overall, results from this study showed that clinical practice in our hospital changed over 
time. Adherence to CP in the choice of empirical antibiotic therapy appeared to reduce over 
time, while main diagnostic and therapeutic interventions (i.e. PSI calculation, execution of 
urinary antigen tests, administration of oxygen therapy) improved. 
These mixed results may explain why in-hospital and 30-day mortality did not significantly 
change in 2012 compared to 2005. Mortality did not appear to be associated with compliance 
to CP, except for performance of urinary antigen test, but did show association with patient 
age and CAP severity. It is possible that impact on mortality due to poor compliance with 
guideline recommended antibiotic therapy could have been cancelled out by improvements in 
compliance with other diagnostic and therapeutic interventions. 
Reduced adherence to CP empiric antibiotic therapy in 2012 compared to 2005 may be due to 
lack of dedicated resources available for implementation of the clinical guidelines. Although 
recently in Italy there have been some efforts to promote implementation of clinical 
guidelines, [34] the frequency and quality of dissemination is still subject to local initiative. A 
recent Italian study [35] found that implementation of therapeutic recommendations, 
including empirical antibiotic therapy, led to significantly better outcomes of CAP and/or 
return to prior health status, especially in more severe cases of CAP.  
Limitations of our study 
Our study limitations primarily stem from the observational study design, although we have 
accounted for the most common potential confounders of the association between adherence 
to CAP CP and clinical outcomes. As in any retrospective study, missing data can influence 
the effect size of associations as well as their precision. Particularly, the data relating to 
administration of antibiotics within 4 hours from access to A&E and data about 
pneumococcal and influenza vaccinations were only partially complete, and such variables 
could not be accounted for in the analyses. However, most variables were carefully recorded 
and could be included in the analyses. 
In 2005 the majority (62.96%) of CAP patients were treated in the hospital’s respiratory ward, 
while in 2012, due to a hospital-wide reorganisation, all CAP patients were treated in non-
respiratory wards. This could have potentially influenced both adherence to CAP CP and the 
clinical outcomes assessed in our study. However, we have accounted for this potential 
confounding effect by including ward type in the regression model. 
 
CONCLUSION 
 
Adherence to CAP guidelines can progressively change over time, suggesting the need for 
continual efforts to promote compliance with clinical guidelines. 
In our study, mortality was not associated with compliance to the clinical pathway, but 
appeared positively associated with patient age and CAP severity, and negatively associated 
with performance of urinary antigen tests. Adherence to CP empirical antibiotic treatment 
was associated with lower length of hospital stay and shorter duration of antibiotic therapy, 
suggesting overall improvement in clinical care with adherence to the CP. Ongoing and 
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comprehensive approaches to favour guidelines implementation may result in improvement 
of the overall management of CAP and help reduce burden on hospital services. 
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Table 1. Socio-demographic and clinical characteristics of the sample 
 2005 2012 total p-value 
Age in years, mean (SD) 69.03 (20.69) 75.36 (15.58) 72.64 (18.22)  < 0.0001 
Sex, % (n) 
male 
female 
 
57.61 (140) 
42.39 (103) 
 
56.39 (181) 
43.61 (140) 
 
56.91 (321) 
43.09 (243) 
 
0.771 
Admission from, % (n) 
home 
nursing home 
 
90.95 (221) 
9.05 (22) 
 
85.98 (276) 
14.02 (45) 
 
88.12 (497) 
11.88 (67) 
 
0.071 
Smoking, % (n) 
smokers 
never smokers 
ex smokers 
not assessed 
 
20.58 (50) 
38.68 (94) 
20.16 (49) 
20.58 (50) 
 
16.20 (52) 
35.83 (115) 
29.28 (94) 
18.69 (60) 
 
18.09 (102) 
37.06 (209) 
25.35 (143) 
19.50 (110) 
0.087 
Comorbidity, % (n) 
systemic hypertension 
ischemic cardiopathy 
heart failure 
cerebrovascular disease 
diabetes mellitus 
malignancy 
chronic liver disease 
chronic kidney disease 
chronic lung disease 
non-neoplastic haematological disease* 
diseases non otherwise classified 
≥ 5 comorbidities 
 
36.21 (88) 
17.28 (42) 
19.34 (47) 
18.11 (44) 
16.05 (39) 
11.52 (28) 
9.05 (22) 
13.99 (34) 
24.69 (60) 
2.06 (5) 
65.02 (158) 
9.05 (22) 
 
51.40 (165) 
19.00 (61) 
25.55 (82) 
35.20 (113) 
21.18 (68) 
24.92 (80) 
11.53 (37) 
12.15 (39) 
28.66 (92) 
6.54 (21) 
76.01 (244) 
19.31 (62) 
 
44.86 (253) 
18.26 (103) 
22.87 (129) 
27.84 (157) 
18.97 (107) 
19.15 (108) 
10.46 (59) 
12.94 (73) 
26.95 (152) 
4.61 (26) 
71.28 (402) 
14.89 (84) 
 
< 0.001 
0.601 
0.082 
< 0.001 
0.124 
< 0.001 
0.342 
0.519 
0.293 
0.012 
0.004 
0.001 
Note: in bold are the variables for which there is evidence at the 5% level of a difference between 2005 and 2012 
* non-immunosuppressive non-neoplastic haematological disease such as anemia and myelodysplastic diseases 
 
Tables
Table 2. Radiological aspects of pneumonia and criteria for severe CAP 
 2005 2012 total p-value 
Radiological aspect, % (n)     
XR monolateral infiltrates 
XR bilateral infiltrates 
79.83 (190) 
20.17 (48) 
80.70 (255) 
19.30 (61) 
80.32 (445) 
19.68 (109) 
0.800 
pleuric effusion 31.69 (77) 30.22 (97) 30.85 (174) 0.708 
pleuric empyema 3.29 (8) 3.12 (10) 3.19 (18) 0.906 
Criteria for severe CAP, % (n) 
invasive mechanical ventilation 
septic shock 
respiratory rate > 30 breaths/minute 
paO2/FiO2 < 250 
multilobar infiltrates 
confusion/disorientation 
uremia (Blood Urea Nitrogen > 20 mg/dl) 
leukopenia (WBC < 4000/mm3) 
thrombocytopenia (platelets < 100000/mm3) 
hypothermia (body temperature < 36°C) 
systolic blood pressure < 90 mmHg 
 
1.65 (4) 
2.47 (6) 
7.82 (19) 
0.41 (1) 
25.51 (62) 
20.16 (49) 
26.75 (65) 
6.17 (15) 
8.64 (21) 
0 
2.47 (6) 
 
1.25 (4) 
2.18 (7) 
0.93 (3) 
0.62 (2) 
24.30 (78) 
19.00 (61) 
3.12 (10) 
4.36 (14) 
6.54 (21) 
0 
4.05 (13) 
 
1.42 (8) 
2.30 (13) 
3.90 (22) 
0.53 (3) 
24.82 (140) 
19.50 (110) 
13.30 (75) 
5.14 (29) 
7.45 (42) 
0 
3.37 (19) 
 
0.691 
0.821 
< 0.001 
0.732 
0.741 
0.730 
< 0.001 
0.335 
0.347 
- 
0.303 
severe CAP as defined by ATS*, % (n) 
at least 1 major criteria 
at least 2 of the first 3 minor criteria 
at least 3 minor criteria 
10.70 (26) 
3.29 (8) 
1.23 (3) 
9.05 (22) 
5.61 (18) 
3.12 (10) 
2.18 (7) 
2.18 (7) 
7.80 (44) 
3.19 (18) 
1.77 (10) 
5.14 (29) 
0.026 
0.906 
0.399 
< 0.001 
Note: in bold are the variables for which there is evidence at the 5% level of a difference between 2005 and 2012 
*American Thoracic Society 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Adherence to diagnostic procedures and its main findings 
 2005 2012 total p-value 
PSI (Pneumonia Severity Index) calculation, % (n) 17.70 (43) 25.23 (81) 21.99 (124) 0.032 
I class 
II class 
III class 
IV class 
V class 
4.65 (2) 
4.65 (2) 
13.95 (6) 
60.47 (26) 
16.28 (7) 
12.35 (10) 
8.64 (7) 
20.99 (17) 
37.04 (30) 
20.99 (17) 
9.68 (12) 
7.26 (9) 
18.55 (23) 
45.16 (56) 
19.35 (24) 
0.146 
History investigation about vaccinations, % (n) 0.41 (1) 0 0.01 (1) 0.250 
Procedures for etiological diagnosis, % (n)     
blood culture 60.91 (148) 64.17 (206) 62.77 (354) 0.426 
positive 24.32 (36) 9.71 (20) 15.82 (56) < 0.001 
S. pneumoniae 
S. aureus 
coagulase-negative Staphylococci 
Pseudomonas vesicularis 
Enterobacteriaceae 
Saprophytic 
2.78 (1) 
2.78 (1) 
66.67 (24) 
2.78 (1) 
8.33 (3) 
16.67 (6) 
35.00 (7) 
10.00 (2) 
40.00 (8) 
0 
5.00 (1) 
10.00 (2) 
14.29 (8) 
5.36 (3) 
57.14 (32) 
1.79 (1) 
7.14 (4) 
14.29 (8) 
0.020 
urinary antigen test for S. pneumoniae 
positive 
urinary antigen test for L. pneumophila 
positive 
sputum Gram stain 
sputum culture 
lung brushing or biopsy 
bronchoalveolar lavage (BAL) 
bronchial lavage (BL) 
quantitative endotracheal aspirate 
other 
22.63 (55) 
3.64 (2) 
48.56 (118) 
1.69 (2) 
19.75 (48) 
29.63 (72) 
4.94 (12) 
4.94 (12) 
10.70 (26) 
1.23 (3) 
61.73 (150) 
56.39 (181) 
6.08 (11) 
57.63 (185) 
4.32 (8) 
0.93 (3) 
19.31 (62) 
1.25 (4) 
8.72 (28) 
0.31 (1) 
2.49 (8) 
45.17 (145) 
41.84 (236) 
5.51 (13) 
53.72 (303) 
3.30 (10) 
9.04 (51) 
23.76 (134) 
2.84 (16) 
7.09 (40) 
4.79 (27) 
1.95 (11) 
52.30 (295) 
< 0.001 
0.487 
0.032 
0.212 
< 0.001 
0.004 
0.009 
0.083 
< 0.001 
0.285 
< 0.001 
Procedures for pleural effusion/empyema, % (n) 
thoracentesis 
chest drainage 
video-assisted thoracic surgery 
 
22.35 (19) 
9.41 (8) 
37.50 (3) 
 
14.95 (16) 
9.35 (10) 
10.00 (1) 
 
18.23 (35) 
9.38 (18) 
22.22 (4) 
 
0.187 
0.988 
0.163 
Note: in bold are the variables for which there is evidence at the 5% level of a difference between 2005 and 2012 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Adherence to therapeutic interventions 
 2005 2012 total p-value 
Distribution of patients within clinical categories 
identified by guidelines % (n) 
1) inpatient, non-ICU* treatment 
2) patient with suspected aspiration from home 
3) patient with suspected aspiration from nursing home or in 
ICU treatment 
4) patient with suspected P. aeruginosa infection 
5) inpatient, ICU treatment without risk for P. aeruginosa 
infection 
6) inpatient, ICU treatment with risk for P. aeruginosa 
infection 
96.71 (235) 
1.23 (3) 
0.41 (1) 
 
0.41 (1) 
1.23 (3) 
 
- 
96.26 (309) 
0.62 (2) 
1.56 (5) 
 
1.25 (4) 
- 
 
0.31 (1) 
96.45 (544) 
0.89 (5) 
1.06 (6) 
 
0.89 (5) 
0.53 (3) 
 
0.18 (1) 
0.151 
Antibiotic therapy adherent to guidelines, % (n)     
in patients of category 1 70.26 (163) 58.58 (181) 63.59 (344) 0.005 
in patients of category 2 33.33 (1) 0 20.00 (1) 0.361 
in patients of category 3 0 0 0 - 
in patients of category 4 0 25.00 (1) 20.00 (1) 0.576 
in patients of category 5 33.33 (1)  - 33.33 (1) - 
in patients of category 6 - 0 0 - 
Administration of the first antibiotic dose, % (n) 
within 4 hours from A&E presentation 
within 4 hours from admission to ward 
 
96.00 (24) 
54.92 (106) 
 
 99.59 (243) 
69.66 (202) 
 
99.26 (267) 
63.77 (308) 
 
0.047 
< 0.001 
Switch therapy, % (n) 23.31 (55) 30.94 (99) 27.70 (154) 0.047 
Intra-hospital antibiotic therapy duration in days, mean (SD) 10.71 (7.17) 10.56 (6.39) 10.63 (6.73) 0.7925 
Post-discharge prescription duration in days, mean (SD) 6.20 (2.52) 4.79 (2.33) 5.39 (2.33) < 0.0001 
Antibiotic therapy total duration in days, mean (SD) 13.66 (8.18) 12.78 (6.65) 13.14 (7.33) 0.1825 
Oxygen administration, % (n) 
MV (mechanical ventilation), % (n) 
58.85 (143) 
2.06 (5) 
75.70 (243) 
9.35 (30) 
68.44 (386) 
6.21 (35) 
< 0.001 
< 0.001 
Administration of low molecular weight heparin, % (n) 53.09 (129) 58.88 (189) 56.38 (318) 0.170 
Note: in bold are the variables for which there is evidence at the 5% level of a difference between 2005 and 2012 
* Intensive Care Unit 
  
  
Table 5. Multivariable regression analyses for in-hospital and 30-day mortality, length of hospital stay and duration of antibiotic 
therapy 
  
in-hospital mortality 30-day mortality length of hospital stay 
duration of antibiotic 
therapy  
  N=561 N=495 N=561 N=505 
  OR 95%CI OR 95%CI MD 95%CI MD 95%CI 
Socio-demographic characteristics and other potential confounders 
 Age in years (continuous) 1.081 1.049,1.114 1.105 1.068,1.143 0.052 0.016,0.089 -0.003 -0.038,0.033 
 Male gender (vs. female 
gender) 
0.803 0.454,1.419 0.628 0.348,1.133 0.850 -0.424,2.124 0.411 -0.792,1.615 
 Admission from nursing 
home (vs. from own home) 
1.118 0.544,2.300 1.409 0.648,3.063 -3.222 -5.232,-1.213 -1.770 -3.619,0.079 
 Five or more comorbidities 
(vs. less than five) 
1.601 0.827,3.102 1.243 0.627,2.464 1.150 -0.621,2.921 1.421 -0.233,3.075 
 ATS criteria for CAP 
severity (continuous) 
1.743 1.383,2.196 1.868 1.462,2.385 -0.287 -0.903,0.329 -1.111 -1.694,-0.527 
 Admission in 2012 (vs. 
admission in 2015) 
1.081 0.491,2.377 0.863 0.387,1.923 1.297 -0.723,3.318 0.659 -1.224,2.541 
 Stay in a respiratory ward 
(vs. stay in a non-respiratory 
ward) 
0.847 0.351,2.042 0.750 0.304,1.851 4.225 2.152,6.299 4.363 2.377,6.349 
 Mechanical Ventilation 0.968 0.289,3.243 1.102 0.340,3.575 4.638 1.688,7.587 5.017 2.115,7.919 
Adherence to diagnostic procedures 
 Blood culture 0.677 0.377,1.213 0.600 0.328,1.097 2.631 1.259,4.003 2.728 1.417,4.039 
 Urinary Antigen tests 0.427 0.215,0.850 0.341 0.170,0.685 0.033 -1.407,1.473 -0.164 -1.535,1.207 
Adherence to therapeutic interventions 
 Antibiotic therapy adherent 
to clinical pathway 
0.830 0.468,1.471 0.957 0.526,1.738 -2.868 -4.186,-1.550 -2.004 -3.265,-0.743 
 Treatment in ICU 0.452 0.073,2.817 0.305 0.047,1.983 8.409 3.547,13.272 6.237 1.170,11.303 
Note: in bold are the variables for which there is evidence at the 5% level of a difference between 2005 and 2012 
  
